New blood test matches gold standard for liver disease diagnosis
The test's performance on routine blood samples matched that of magnetic resonance elastography, the most accurate non-invasive method for assessing liver disease.
An experimental blood test called LiquidTransformer, developed by Hepta, can accurately determine the extent of chronic liver disease from a routine blood sample, according to researchers presenting at the AASLD meeting in Denver. The test's performance matches that of magnetic resonance elastography (MRE), the most accurate non-invasive method for assessing liver disease, which is largely confined to specialist centers and clinical trials.
LiquidTransformer determines liver biology from DNA circulating in blood, providing a non-invasive alternative to MRE or liver biopsy for staging metabolic dysfunction-associated steatohepatitis (MASH), a condition involving inflammation and scarring that can advance to cirrhosis and liver failure.
Brief written by urgent.news from ETHealthworld's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
